STAT China: Two more Hong Kong IPO filings, and Beijing’s latest drug price cuts
In this edition, more IPO filings, Beijing’s latest drug price cuts, and a renewed genomics patent feud between BGI and Illumina.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario